Key Points
- CEO sale: Compugen CEO Eran Ophir sold 5,625 shares on April 1 at an average price of $2.21 for $12,431.25, cutting his stake by 33.09% to 11,375 shares valued at $25,138.75; the trade was made under a pre-arranged Rule 10b5-1 plan and disclosed to the SEC.
- Quarterly beat but mixed outlook: Compugen reported strong results for the quarter — $0.60 EPS vs. $0.05 expected and $67.33M revenue vs. $14.30M expected — yet analysts still forecast -0.03 EPS for the current year.
- Market and analyst context: The stock has a $213.68M market cap and a 52-week range of $1.13–$2.38, with mixed analyst coverage (average rating "Moderate Buy" and an average price target of $4.00).
Compugen Ltd. (NASDAQ:CGEN - Get Free Report) CEO Eran Ophir sold 5,625 shares of the business's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $2.21, for a total transaction of $12,431.25. Following the completion of the transaction, the chief executive officer directly owned 11,375 shares in the company, valued at $25,138.75. This trade represents a 33.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Compugen Stock Performance
Shares of NASDAQ:CGEN opened at $2.26 on Friday. The firm has a market cap of $213.68 million, a price-to-earnings ratio of 6.11 and a beta of 2.77. The firm has a fifty day moving average price of $1.96 and a 200 day moving average price of $1.77. Compugen Ltd. has a fifty-two week low of $1.13 and a fifty-two week high of $2.38.
Compugen (NASDAQ:CGEN - Get Free Report) last announced its quarterly earnings results on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.05 by $0.55. The company had revenue of $67.33 million for the quarter, compared to the consensus estimate of $14.30 million. Compugen had a net margin of 48.57% and a return on equity of 55.68%. As a group, research analysts predict that Compugen Ltd. will post -0.03 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. purchased a new stake in shares of Compugen in the second quarter valued at $56,000. Jane Street Group LLC boosted its stake in shares of Compugen by 1,077.0% during the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company's stock worth $700,000 after purchasing an additional 359,785 shares during the period. Osaic Holdings Inc. grew its holdings in Compugen by 346.0% during the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company's stock valued at $78,000 after purchasing an additional 34,045 shares during the last quarter. Two Sigma Investments LP grew its holdings in Compugen by 10.6% during the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company's stock valued at $291,000 after purchasing an additional 18,929 shares during the last quarter. Finally, Raymond James Financial Inc. raised its position in Compugen by 51.0% in the 3rd quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company's stock worth $149,000 after purchasing an additional 34,215 shares during the period. Institutional investors own 12.22% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on CGEN shares. Wall Street Zen raised Compugen from a "hold" rating to a "buy" rating in a report on Saturday, March 7th. Truist Financial raised Compugen to a "strong-buy" rating in a research note on Wednesday, March 25th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Compugen in a research note on Wednesday, January 21st. Finally, HC Wainwright assumed coverage on Compugen in a report on Wednesday, January 7th. They set a "buy" rating and a $4.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Compugen has an average rating of "Moderate Buy" and an average price target of $4.00.
Get Our Latest Stock Analysis on Compugen
Compugen Company Profile
(
Get Free Report)
Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.
Compugen's predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
